跳转至内容
Merck
所有图片(1)

Key Documents

View All Documentation

S5701

Sigma-Aldrich

SR 49059

≥97% (HPLC)

别名:

(2S)-1-[[(2r,3s)-5-氯-3-(2-氯苯基)-1-[(3,4-二甲氧基苯基)磺酰基]-2,3-二氢-3-羟基-1H-吲哚-2-基]羰基]-2-吡咯烷羧酰胺, SR49059

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C28H27Cl2N3O7S
CAS号:
150375-75-0
分子量:
620.50
MDL號碼:
MFCD00922133
分類程式碼代碼:
51111800
PubChem物質ID:
329824460
NACRES:
NA.77

化驗

≥97% (HPLC)

形狀

powder

光學活性

[α]/D -180 to -190°, c = 0.3 in chloroform-d

顏色

white to off-white

溶解度

DMSO: ≥10 mg/mL

起源

Sanofi Aventis

儲存溫度

2-8°C

SMILES 字串

COc1ccc(cc1OC)S(=O)(=O)N2[C@@H](C(=O)N3CCC[C@H]3C(N)=O)[C@@](O)(c4ccccc4Cl)c5cc(Cl)ccc25

InChI

1S/C28H27Cl2N3O7S/c1-39-23-12-10-17(15-24(23)40-2)41(37,38)33-21-11-9-16(29)14-19(21)28(36,18-6-3-4-7-20(18)30)25(33)27(35)32-13-5-8-22(32)26(31)34/h3-4,6-7,9-12,14-15,22,25,36H,5,8,13H2,1-2H3,(H2,31,34)/t22-,25-,28+/m0/s1

InChI 密鑰

CEBYCSRFKCEUSW-NAYZPBBASA-N

基因資訊

human ... AVPR1A(552) , OXTR(5021)

應用

SR 49059可用于精氨酸加压素（AVP）V1a受体介导的细胞信号转导研究中。
SR 49059已用于研究V1AR（1A型加压素受体）信号传导介导的 β肾上腺素能受体反应性及其对心力衰竭发展的影响。

生化／生理作用

SR 49059是一种有效的选择性精氨酸后叶加压素(AVP) V1a-受体拮抗剂。AVP是一种激素，在循环和水的稳态中发挥重要作用，并且在充血性心力衰竭（CHF）中对肾脏血流动力学改变、保水力和心脏重塑等具有重要作用。AVP受体有三种亚型，即V1a、V1b和V2。它们均属于大型视紫红质样G蛋白偶联受体家族。V(1a)拮抗剂可改善CHF中的水平衡和心脏肥大，可能有益于CHF中的保水力和心脏重塑。SR 49059在治疗雷诺氏病、痛经和安胎方面也显示出初步的积极结果。

特點和優勢

该化合物由Sanofi Aventis开发。要浏览其他药物开发化合物和批准的药物/候选药物列表，单击此处。

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

nwg

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Piotr Pierzynski
Reproductive biomedicine online, 22(1), 9-16 (2010-12-07)
Embryo transfer, the final stage of IVF/embryo transfer (IVF/ET) treatment, independently influences treatment outcome.Successful embryo implantation following embryo transfer, among other factors, is also dependant on uterine receptivity.Uterine contractile activity may adversely affect the implantation. Although increased contractions have been
Margareta Steinwall et al.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 20(2), 104-109 (2005-04-13)
Relcovaptan (SR 49059) is a non-peptide, orally active vasopressin V1a receptor inhibitor. The effect on uterine contractions in 18 women with preterm labor in pregnancy weeks 32-36 was assessed in a double-blind investigation. The inclusion criterion was at least four
Véronique Perraudin et al.
The Journal of clinical endocrinology and metabolism, 91(4), 1566-1572 (2006-02-02)
Arginine vasopressin (AVP) stimulates steroid secretion from the normal human adrenal gland and some cortisol-producing adrenocortical tumors or hyperplasia through activation of the V(1a) receptor. The objective of the study was to investigate in vitro and in vivo the possible
Virginie Bernier et al.
Journal of the American Society of Nephrology : JASN, 17(1), 232-243 (2005-12-02)
In many mendelian diseases, some mutations result in the synthesis of misfolded proteins that cannot reach a transport-competent conformation. In X-linked nephrogenic diabetes insipidus, most of the mutant vasopressin 2 (V2) receptors are trapped in the endoplasmic reticulum and degraded.
J H Robben et al.
American journal of physiology. Renal physiology, 292(1), F253-F260 (2006-08-24)
Intracellular retention of a functional vasopressin V2 receptor (V2R) is a major cause of congenital nephrogenic diabetes insipidus (NDI) and rescue of V2R mutants by nonpeptide antagonists may restore their basolateral membrane (BM) localization and function. However, the criteria for
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门